文献速递心脑血管急症重症综合管理与镇静镇痛

急性心肌梗死中的血管紧张素受体-脑啡肽酶抑制

Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
PubMed 文献 · N Engl J Med · 2021-01-01
一句话结论在急性心肌梗死合并左室射血分数降低、肺淤血或两者兼有的患者中,沙库巴曲缬沙坦较雷米普利未显著降低心血管死亡或新发心力衰竭发生率(HR 0.90,95%CI 0.78–1.04,P=0.17)。

PARADISE-MI试验将5661例急性心肌梗死合并左室射血分数降低、肺淤血或两者兼有的患者随机分配至沙库巴曲缬沙坦(沙库巴曲97 mg/缬沙坦103 mg,每日两次)或雷米普利(5 mg,每日两次)组,在推荐治疗基础上加用。中位随访22个月,主要终点(心血管死亡或新发心力衰竭)在沙库巴曲缬沙坦组338例(11.9%)、雷米普利组373例(13.2%)(HR 0.90;95%CI 0.78–1.04;P=0.17)。因不良事件停药在沙库巴曲缬沙坦组357例(12.6%)、雷米普利组379例(13.4%)。沙库巴曲缬沙坦未显著降低急性心肌梗死后主要终点事件风险。

要点

  • 急性心梗合并左室射血分数降低、肺淤血或两者兼有者,沙库巴曲缬沙坦较雷米普利未显著降低心血管死亡或新发心衰(11.9% vs 13.2%;HR 0.90;95%CI 0.78–1.04;P=0.17)。
  • 心血管死亡或心衰住院:沙库巴曲缬沙坦组10.9% vs 雷米普利组11.8%(HR 0.91;95%CI 0.78–1.07)。
  • 心血管死亡:沙库巴曲缬沙坦组5.9% vs 雷米普利组6.7%(HR 0.87;95%CI 0.71–1.08);全因死亡:7.5% vs 8.5%(HR 0.88;95%CI 0.73–1.05)。
  • 因不良事件停药:沙库巴曲缬沙坦组12.6% vs 雷米普利组13.4%。
  • 沙库巴曲缬沙坦方案为沙库巴曲97 mg/缬沙坦103 mg每日两次,雷米普利5 mg每日两次,均在推荐治疗基础上加用。

适用人群与场景

  • 急性心肌梗死合并左室射血分数降低、肺淤血或两者兼有的患者。

处置流程与药物剂量

  • 沙库巴曲缬沙坦组:沙库巴曲97 mg/缬沙坦103 mg,每日两次,口服,在推荐治疗基础上加用。
  • 雷米普利组:雷米普利5 mg,每日两次,口服,在推荐治疗基础上加用。

研究设计与关键结果

  • PARADISE-MI为随机对照试验,共5661例患者随机分组:沙库巴曲缬沙坦组2830例,雷米普利组2831例。
  • 中位随访22个月,主要终点(心血管死亡或新发心力衰竭,以先发生者为准)在沙库巴曲缬沙坦组338例(11.9%)、雷米普利组373例(13.2%)(HR 0.90;95%CI 0.78–1.04;P=0.17)。
  • 心血管死亡或心衰住院:沙库巴曲缬沙坦组308例(10.9%)vs 雷米普利组335例(11.8%)(HR 0.91;95%CI 0.78–1.07)。
  • 心血管死亡:沙库巴曲缬沙坦组168例(5.9%)vs 雷米普利组191例(6.7%)(HR 0.87;95%CI 0.71–1.08)。
  • 全因死亡:沙库巴曲缬沙坦组213例(7.5%)vs 雷米普利组242例(8.5%)(HR 0.88;95%CI 0.73–1.05)。
  • 因不良事件停药:沙库巴曲缬沙坦组357例(12.6%)vs 雷米普利组379例(13.4%)。

证据类型、等级与局限

  • 证据类型:随机对照试验(PARADISE-MI,ClinicalTrials.gov NCT02924727),由诺华资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在急性心肌梗死合并左室射血分数降低、肺淤血或两者兼有的患者中,沙库巴曲缬沙坦较雷米普利未显著降低心血管死亡或新发心力衰竭发生率,作者结论为沙库巴曲缬沙坦与雷米普利相比未显著降低主要终点事件。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In patients with symptomatic heart failure, sacubitril-valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting-enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking.

METHODS: We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first.

RESULTS: A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril-valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril-valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P = 0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril-valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91; 95% CI, 0.78 to 1.07); death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril-valsartan group and 379 patients (13.4%) in the ramipril group.

CONCLUSIONS: Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction. (Funded by Novartis; PARADISE-MI ClinicalTrials.gov number, NCT02924727.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021. PMID: 34758252. doi:10.1056/NEJMoa2104508

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。